Jan/Feb, 2016. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Acta Polytechnica 00(0):1–8, 0000 © Czech Technical University in Prague, 2015 PREPRINT 2015-09-24 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 9...

CO RR EC TE D PR O O F 01 59 02 60 03 61 04 62 05 63 06 64 07 65 08 66 09 67 10 68 11 69 12 70 13 71 14 72 15 73 16 74 17 75 18 76 19 77 20 78 21 79 22 80 23 81 24 82 25 83 26 84 27 85 28 86 29 87 30 88 31 89 32 90 33 91 34 92 35 93 36 94 37 95 38 96 39 97 40 98 41 99 42 100 43 101 44 102 45 103 46 104 47 105 48 106 49 107 50 108 51 109 52 110 53 111 54 112 55 113 56 114 57 115 58 116 Journal C...

Previous studies from this group have shown that limit size lipid-based systems – defined as the smallest achievable aggregates compatible with the packing properties of their molecular constituents – can be efficiently produced using rapid microfluidic mixing technique. In this work, it is shown that similar procedures can be employed for the production of homogeneously sized unilamellar vesic...

Great strides were made during the last century in the management of diabetes in pregnancy. Before the discovery of insulin in 1921 the outlook for the diabetic mother and her fetus was abysmal. With the advent of insulin, an emphasis on a team approach to care, improved methods of fetal surveillance, and a focus on metabolic normalisation brought about by intensive insulin regimens and home gl...

N-Methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide (axitinib) is an oral inhibitor of vascular endothelial growth factor receptors 1–3, which is approved for the treatment of advanced renal cell cancer. Human [C]-labeled clinical studies indicate axitinib’s primary route of clearance is metabolism. The aims of the in vitro experiments presented herein were to identify an...

CO RR EC TE D PR O O F 01 63 02 64 03 65 04 66 05 67 06 68 07 69 08 70 09 71 10 72 11 73 12 74 13 75 14 76 15 77 16 78 17 79 18 80 19 81 20 82 21 83 22 84 23 85 24 86 25 87 26 88 27 89 28 90 29 91 30 92 31 93 32 94 33 95 34 96 35 97 36 98 37 99 38 100 39 101 40 102 41 103 42 104 43 105 44 106 45 107 46 108 47 109 48 110 49 111 50 112 51 113 52 114 53 115 54 116 55 117 56 118 57 119 58 120 59 12...

CO RR EC TE D PR O O F 01 59 02 60 03 61 04 62 05 63 06 64 07 65 08 66 09 67 10 68 11 69 12 70 13 71 14 72 15 73 16 74 17 75 18 76 19 77 20 78 21 79 22 80 23 81 24 82 25 83 26 84 27 85 28 86 29 87 30 88 31 89 32 90 33 91 34 92 35 93 36 94 37 95 38 96 39 97 40 98 41 99 42 100 43 101 44 102 45 103 46 104 47 105 48 106 49 107 50 108 51 109 52 110 53 111 54 112 55 113 56 114 57 115 58 116 Journal C...

CO RR EC TE D PR O O F 01 59 02 60 03 61 04 62 05 63 06 64 07 65 08 66 09 67 10 68 11 69 12 70 13 71 14 72 15 73 16 74 17 75 18 76 19 77 20 78 21 79 22 80 23 81 24 82 25 83 26 84 27 85 28 86 29 87 30 88 31 89 32 90 33 91 34 92 35 93 36 94 37 95 38 96 39 97 40 98 41 99 42 100 43 101 44 102 45 103 46 104 47 105 48 106 49 107 50 108 51 109 52 110 53 111 54 112 55 113 56 114 57 115 58 116 Journal C...